653 related articles for article (PubMed ID: 11961977)
21. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
Appetecchia M; Baldelli R
J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
[TBL] [Abstract][Full Text] [Related]
22. Expression of somatostatin and somatostatin receptor subtypes in Apolipoprotein D (ApoD) knockout mouse brain: An immunohistochemical analysis.
Rajput PS; Billova S; Patel SC; Kharmate G; Somvanshi RK; Kumar U
J Chem Neuroanat; 2009 Sep; 38(1):20-33. PubMed ID: 19465111
[TBL] [Abstract][Full Text] [Related]
23. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects of somatostatin.
Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
26. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
29. Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs.
Arne G; Nilsson B; Dalmo J; Kristiansson E; Arvidsson Y; Forssell-Aronsson E; Nilsson O; Ahlman H
Acta Oncol; 2013 May; 52(4):783-92. PubMed ID: 23116418
[TBL] [Abstract][Full Text] [Related]
30. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
31. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
34. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
35. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
36. Physiology of somatostatin receptors.
Guillermet-Guibert J; Lahlou H; Cordelier P; Bousquet C; Pyronnet S; Susini C
J Endocrinol Invest; 2005; 28(11 Suppl International):5-9. PubMed ID: 16625838
[TBL] [Abstract][Full Text] [Related]
37. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
[No Abstract] [Full Text] [Related]
38. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
Reubi JC
Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
[TBL] [Abstract][Full Text] [Related]
40. Peptide receptor expression in GEP-NET.
Reubi JC
Virchows Arch; 2007 Aug; 451 Suppl 1():S47-50. PubMed ID: 17684767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
